New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2013
12:31 EDTCLMT, SONC, ZIOP, BRK.A, RFMD, GSOn The Fly: Midday Wrap
Stocks on Wall Street were higher right out of the gate and have not moved far from their opening levels near midday. Investors received a fair amount of domestic economic data, including better than expected reports on home prices and durable goods orders. The flip side, however, was some worse than expected consumer confidence and new home sales data. Despite the mixed data, the market seems intent on closing the quarter with its gains intact as the end of the month approaches... ECONOMIC EVENTS: In the U.S., overall orders for durable goods rose 5.7% in February, versus expectations for an increase of 3.9%. However, excluding transportation, orders slipped 0.5%, versus expectations for a 0.6% rise. The S&P/Case-Shiller 20-city home price index climbed 8.1% in the 12 months ending in January, after rising 6.8% a month earlier. New home sales dropped 4.6% to 411K in February, versus expectations for a decline to 414K. Consumer confidence fell 8.3 points to 59.7 in March, which was worse than the expected pull back to 69.0. The Richmond Fed manufacturing survey reading of 3 for March missed expectations for it to hold at 6... COMPANY NEWS: Goldman Sachs (GS) announced that it amended its warrant agreement with Berkshire Hathaway (BRK.A) to settle in terms of net shares in place of a cash settlement, quoting Berkshire's Chairman and CEO Warren Buffett as having said, "We intend to hold a significant investment in Goldman Sachs." Shares of Goldman, which rose early in the session, were down fractionally near noon... MAJOR MOVERS: Among the notable gainers were Sonic (SONC), which rose 8% following its earnings report, and RF Micro Devices (RFMD), which rallied nearly 6% after Oppenheimer upgraded the stock to an Outperform rating. Among the noteworthy losers was Ziopharm (ZIOP), which was downgraded by at least four analyst firms and plunged over 61% after terminating development of a cancer drug after a clinical study missed its goal. Also lower were shares of Calumet Specialty Products (CLMT), down 4% after an offering of 5.25M of its shares priced at $37.50... INDICES: Near midday, the Dow was up 74.84, or 0.52%, to 14,522.59; the Nasdaq was up 5.90, or 0.18%, to 3,241.20; and the S&P 500 was up 6.36, or 0.41%, to 1,558.05.
News For A;SONC;RFMD;ZIOP;CLMT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
June 23, 2015
10:46 EDTSONCSonic sees $70M-$80M of free cash flow in FY15
Subscribe for More Information
09:14 EDTSONCOn The Fly: Pre-market Movers
Subscribe for More Information
08:45 EDTSONCSonic revenue momentum impressive, says Sterne Agee CRT
Subscribe for More Information
07:53 EDTSONCSonic reported 'very solid' results, says Oppenheimer
Subscribe for More Information
07:15 EDTSONCOppenheimer to hold a conference
Subscribe for More Information
June 22, 2015
19:00 EDTSONCOn The Fly: After Hours Movers
Subscribe for More Information
17:46 EDTSONCSonic slides over 5% after reporting Q3 results and guidance
Subscribe for More Information
16:07 EDTSONCSonic sees Q4 positive same-store sales in the mid-single digit range
Subscribe for More Information
16:05 EDTSONCSonic sees 27%-29% EPS growth in FY15
Subscribe for More Information
16:04 EDTSONCSonic reports adjusted Q3 EPS 36c, consensus 36c
Reports Q3 revenue $164.7M, consensus $164.17M. Reports Q3 system same-store sales increased 6.1%, consisting of a 6.1% same-store sales increase at franchise drive-ins and an increase of 5.5% at company drive-ins.
15:00 EDTSONCNotable companies reporting after market close
Subscribe for More Information
13:46 EDTSONCSonic technical notes before earnings news
Subscribe for More Information
10:00 EDTZIOPOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:14 EDTZIOPOn The Fly: Pre-market Movers
Subscribe for More Information
07:59 EDTZIOPZiopharm downgraded on valuation, competition at BMO Capital
As noted earlier, BMO Capital downgraded Ziopharm Market Perform from Outperform. As reasons for the downgrade, the firm cited valuation, increased competition, and its belief that the company has fallen further behind its competitors. Target to $10 from $15.
06:29 EDTZIOPZiopharm downgraded to Market Perform from Outperform at BMO Capital
Subscribe for More Information
June 19, 2015
13:34 EDTSONCSonic Automotive management to meet with Stephens
Subscribe for More Information
08:30 EDTZIOPZiopharm data positive, says BMO Capital
Subscribe for More Information
June 17, 2015
08:45 EDTABofA/Merrill life sciences analysts hold an analyst/industry conference call
Subscribe for More Information
08:32 EDTAAgilent to participate in a conference call with Janney Capital
Janney Capital hosts a conference call with Agilent Technologies' President & CEO, Michael McMullen, on June 17 at 12 pm.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use